An Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of the Phase 2 Formulation of CORT125134 Capsules in Healthy Male Subjects
Latest Information Update: 25 Oct 2023
At a glance
- Drugs Relacorilant (Primary)
- Indications Cushing syndrome; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
Most Recent Events
- 25 Oct 2023 New trial record